company background image
AMRX

Amneal Pharmaceuticals NYSE:AMRX Stock Report

Last Price

US$2.34

Market Cap

US$704.3m

7D

-8.9%

1Y

-42.8%

Updated

08 Dec, 2022

Data

Company Financials +
AMRX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AMRX Stock Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.

Amneal Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amneal Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.34
52 Week HighUS$5.13
52 Week LowUS$1.95
Beta1.31
1 Month Change0.43%
3 Month Change1.30%
1 Year Change-42.79%
3 Year Change-53.57%
5 Year Changen/a
Change since IPO-84.41%

Recent News & Updates

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Recent updates

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of Debt

Apr 16
Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of Debt

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Nov 23
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Is Amneal Pharmaceuticals (NYSE:AMRX) A Risky Investment?

Apr 28
Is Amneal Pharmaceuticals (NYSE:AMRX) A Risky Investment?

What Percentage Of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Shares Do Insiders Own?

Feb 28
What Percentage Of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Shares Do Insiders Own?

A Closer Look At Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) Uninspiring ROE

Feb 05
A Closer Look At Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) Uninspiring ROE

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Jan 10
These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Are Amneal Pharmaceuticals's (NYSE:AMRX) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Dec 06
Are Amneal Pharmaceuticals's (NYSE:AMRX) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Shareholder Returns

AMRXUS PharmaceuticalsUS Market
7D-8.9%-0.3%-2.8%
1Y-42.8%14.1%-19.6%

Return vs Industry: AMRX underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: AMRX underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is AMRX's price volatile compared to industry and market?
AMRX volatility
AMRX Average Weekly Movement8.7%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: AMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AMRX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20027,000Chirag Patelhttps://www.amneal.com

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Amneal Pharmaceuticals, Inc. Fundamentals Summary

How do Amneal Pharmaceuticals's earnings and revenue compare to its market cap?
AMRX fundamental statistics
Market CapUS$704.34m
Earnings (TTM)-US$132.03m
Revenue (TTM)US$2.14b

0.2x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMRX income statement (TTM)
RevenueUS$2.14b
Cost of RevenueUS$1.38b
Gross ProfitUS$759.37m
Other ExpensesUS$891.40m
Earnings-US$132.03m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.87
Gross Margin35.49%
Net Profit Margin-6.17%
Debt/Equity Ratio1,263.0%

How did AMRX perform over the long term?

See historical performance and comparison